Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

The risk of drug-eluting stent thrombosis with noncardiac surgery

  • 78 Accesses

  • 13 Citations

Abstract

Patients in whom any kind of stent, particularly a drug-eluting stent (DES), was recently implanted are at risk for stent thrombosis when they undergo noncardiac surgery, even months or years after their implantation. The risk of DES thrombosis is likely decreased by delaying noncardiac surgery for as long as possible and continuing dual or at least single antiplatelet therapy in the perioperative period. Preoperative identification and close monitoring of patients with DES may allow prevention and prompt detection and treatment of this catastrophic complication.

This is a preview of subscription content, log in to check access.

References and Recommended Reading

  1. 1.

    Kaluza GL, Joseph J, Lee JR, et al.:Catastrophic outcomes of noncardiac surgery soon after coronary stenting.J Am Coll Cardiol 2000,35:1288–1294.

  2. 2.

    Wilson SH, Fasseas P, Orford JL, et al.:Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.J Am Coll Cardiol 2003,42:234–240.

  3. 3.

    Sharma AK, Ajani AE, Hamwi SM, et al.:Major noncardiac surgery following coronary stenting: when is it safe to operate? Catheter Cardiovasc Intery 2004,63:141–145.

  4. 4.

    Reddy PR, Vaitkus PT:Risks of noncardiac surgery after coronary stenting.Am J Cardiol 2005,95:755–757.

  5. 5.

    Schouten O, Domburg RTV, Bax JJ, et al.:Cardiac outcome after noncardiac surgery in patients with recent coronary stenting.Eur Heart J 2006,27(Suppl 1):86.

  6. 6.

    Kim HL, Park KW, Kwak JJ, et al.:Stent-related cardiac events after non-cardiac surgery: drug-eluting stent vs. bare metal stent.Int J Cardiol 2007 [epub ahead of print].

  7. 7.

    Iakovou I, Schmidt T, Bonizzoni E, et al.:Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.JAMA 2005,293:2126–2130.

  8. 8.

    Daemen J, Wenaweser P, Tsuchida K, et al.:Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.Lancet 2007,369:667–678.

  9. 9.

    Of importance Schouten O, van Domburg RT, Bax JJ, et al.:Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events.J Am Coll Cardiol 2007,49:122–124. One of the largest series of patients who underwent noncardiac surgery after DES implantation. The highest risk for stent thrombosis and cardiac complications was when surgery was performed early after stenting and when antiplatelet therapy was withheld.

  10. 10.

    Marcucci C, Chassot PG, Gardaz JP, et al.:Fatal myocardial infarction after lung resection in a patient with prophylactic preoperative coronary stenting.Br J Anaesth 2004,92:743–747.

  11. 11.

    Eagle KA, Berger PB, Calkins H, et al.:ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).Circulation 2002,105:1257–1267.

  12. 12.

    McFadden EP, Stabile E, Regar E, et al.:Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.Lancet 2004,364:1519–1521.

  13. 13.

    Ong AT, McFadden EP, Regar E, et al.:Late angiographic stent thrombosis (LAST) events with drug-eluting stents.J Am Coll Cardiol 2005,45:2088–2092.

  14. 14.

    Nasser M, Kapeliovich M, Markiewicz W:Late thrombosis of sirolimus-eluting stents following noncardiac surgery.Catheter Cardiovasc Interv 2005,65:516–519.

  15. 15.

    Compton PA, Zankar AA, Adesanya AO, et al.:Risk of noncardiac surgery after coronary drug-eluting stent implantation.Am J Cardiol 2006,98:1212–1213.

  16. 16.

    Bakhru M, Saber W, Brotman D, et al.:Is discontinuation of antiplatelet therapy after 6 months safe in patients with drug-eluting stents undergoing noncardiac surgery? Cleve Clin J Med 2006,73:S23.

  17. 17.

    Hausleiter J, Kastrati A, Mehilli J, et al.:Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries.J Am Coll Cardiol 2002,40:882–889.

  18. 18.

    Mehilli J, Dibra A, Kastrati A, et al.:Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.Eur Heart J 2006,27:260–266.

  19. 19.

    Ardissino D, Cavallini C, Bramucci E, et al.:Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.JAMA 2004,292:2727–2734.

  20. 20.

    Moreno R, Fernandez C, Hernandez R, et al.:Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.J Am Coll Cardiol 2005,45:954–959.

  21. 21.

    Orford JL, Lennon R, Melby S, et al.:Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry.J Am Coll Cardiol 2002,40:1567–1572.

  22. 22.

    Cutlip DE, Baim DS, Ho KK, et al.:Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.Circulation 2001,103:1967–1971.

  23. 23.

    Fujii K, Carlier SG, Mintz GS, et al.:Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study.J Am Coll Cardiol 2005,45:995–998.

  24. 24.

    Cheneau E, Leborgne L, Mintz GS, et al.:Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study.Circulation 2003,108:43–47.

  25. 25.

    Regar E, Lemos PA, Saia F, et al.:Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients.Am J Cardiol 2005,93:1271–1275.

  26. 26.

    Ong AT, Hoye A, Aoki J, et al.:Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.J Am Coll Cardiol 2005,45:947–953.

  27. 27.

    Luscher TF, Steffel J, Eberli FR, et al.:Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.Circulation 2007,115:1051–1058.

  28. 28.

    Kotani J, Awata M, Nanto S, et al.:Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.J Am Coll Cardiol 2006,47:2108–2111.

  29. 29.

    Matsumoto D, Shite J, Shinke T, et al.:Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography.Eur Heart J 2007,28:961–967.

  30. 30.

    Finn AV, Kolodgie FD, Harnek J, et al.:Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.Circulation 2005,112:270–278.

  31. 31.

    Sautter RD, Myers WO, Ray JF 3rd, Wenzel FJ:Relationship of fibrinolytic system to postoperative thrombotic phenomena.Arch Surg 1973,107:292–296.

  32. 32.

    Sametz W, Metzler H, Gries M, et al.:Perioperative catecholamine changes in cardiac risk patients.Eur J Clin Invest 1999,29:582–587.

  33. 33.

    Of importance Grines CL, Bonow RO, Casey DE Jr, et al.:Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.J Am Coll Cardiol 2007,49:734–739. Consensus statement providing practical recommendations about how to manage the antiplatelet regimen of patients receiving DES. Delaying surgery for at least 12 months after DES implantation is recommended.

  34. 34.

    Of major importance McFalls EO, Ward HB, Moritz TE, et al.:Coronary-artery revascularization before elective major vascular surgery.N Engl J Med 2004,351:2795–2804. A landmark randomized trial of preoperative coronary revascularization versus medical therapy alone in patients with stable coronary artery disease undergoing major vascular surgery revealed that there was no short- or long-term benefit derived from coronary revascularization.

  35. 35.

    Ward HB, Kelly RF, Thottapurathu L, et al.:Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery.Ann Thorac Surg 2006,82:795–800; discussion 800–801.

  36. 36.

    Poldermans D, Bax JJ, Schouten O, et al.:Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control? J Am Coll Cardiol 2006,48:964–969.

  37. 37.

    Poldermans D, Schouten O, Vidakovic R, et al.:A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study.J Am Coll Cardiol 2007,49:1763–1769.

  38. 38.

    Brilakis ES, Orford JL, Fasseas P, et al.:Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery.Am J Cardiol 2005,96:512–514.

  39. 39.

    Holmes DR, Jr, Teirstein P, Satler L, et al.: for the SISR Investigators:Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial.JAMA 2006,295:1264–1273.

  40. 40.

    Stone GW, Ellis SG, O’Shaughnessy CD, et al.: for the TAXUS V ISR Investigators:Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within baremetal stents: the TAXUS V ISR randomized trial.JAMA 2006,295:1253–1263.

  41. 41.

    Valerin M, Brennan M, Noll J, et al.:Relationship between aspirin use and postoperative bleeding from dental extractions in a healthy population.Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006,102:326.

  42. 42.

    Ernst A, Eberhardt R, Wahidi M, et al.:Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans.Chest 2006,129:734–737.

  43. 43.

    Kumar N, Jivan S, Thomas P, et al.:Sub-Tenon’s anesthesia with aspirin, warfarin, and clopidogrel.J Cataract Refract Surg 2006,32:1022–1025.

  44. 44.

    Alam M, Goldberg LH:Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy.Dermatol Surg 2002,28:992–998. discussion 998.

  45. 45.

    Dupuis JY, Labinaz M:Noncardiac surgery in patients with coronary artery stent: what should the anesthesiologist know? Can J Anaesth 2005,52:356–361.

  46. 46.

    Jaffe R, Halon DA, Carmeli J, Lewis BS:Prolonged intravenous epitifibatide infusion for prevention of coronary stent thrombosis.Int J Cardiol 2007,114:409–411.

  47. 47.

    Di Nisio M, Bijsterveld NR, Meijers JC, et al.:Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes.J Am Coll Cardiol 2005,46:1582–1583.

  48. 48.

    Mauri L, Hsieh WH, Massaro JM, et al.:Stent thrombosis in randomized clinical trials of drug-eluting stents.N Engl J Med 2007,356:1020–1029.

  49. 49.

    Stone GW, Moses JW, Ellis SG, et al.:Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.N Engl J Med 2007,356:998–1008.

  50. 50.

    Lagerqvist B, James SK, Stenestrand U, et al.:Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.N Engl J Med 2007,356:1009–1019.

  51. 51.

    Patterson L, Hunter D, Mann A:Appropriate waiting time for noncardiac surgery following coronary stent insertion: views of Canadian anesthesiologists.Can J Anaesth 2005,52:440–441.

  52. 52.

    Adesanya AO, de Lemos JA, Greilich NB, Whitten CW:Management of perioperative myocardial infarction in noncardiac surgical patients.Chest 2006,130:584–596.

  53. 53.

    Berger PB, Bellot V, Bell MR, et al.:An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery.Am J Cardiol 2001,87:1100–1102.

Download references

Author information

Correspondence to Emmanouil S. Brilakis MD, PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Brilakis, E.S., Banerjee, S. & Berger, P.B. The risk of drug-eluting stent thrombosis with noncardiac surgery. Curr Cardiol Rep 9, 406 (2007). https://doi.org/10.1007/BF02938368

Download citation

Keywords

  • Clopidogrel
  • Antiplatelet Therapy
  • Bivalirudin
  • Dual Antiplatelet Therapy
  • Noncardiac Surgery